Work

Atorvastatin for the Prevention of Cisplatin-Induced Ototoxicity: A Randomized Controlled Trial

Year: 2026
Type: article
Abstract: Purpose: Cisplatin is used to treat a variety of tumors, it has a significant ototoxic effect; as studies show that about 40% to 70% of patients treated with cisplatin suffer hearing loss to some extent, which may lead to social isolation, anxiety, depression, and an overall negative effect on quality of life. Atorvastatin has a promising otoprotective potential based on preclinical and observational evidence, but the clinical evidence remains limited and not definitive. This is a randomized controlled trial aimed to investigate the efficacy of Atorvastatin co-administered during cisplatin chemotherapy against its ototoxicity in patients with solid tumors. Patients and methods: This randomized controlled trial was conducted at the oncology center and the audio-vestibular unit, Minia university, Egypt, involving 56 patients with different solid tumors scheduled to receive cisplatin. Patients were randomized to receive either Atorvastatin 10 mg daily or no intervention. Baseline and final audiograms were obtained, the primary outcome is to measure change in pure-tone audiometric thresholds from baseline to post-treatment in both groups. The secondary outcome is to assess severity (grade) of hearing loss as well as the subjective hearing impairment in both groups using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) V.6 and the Speech, Spatial, and Qualities of Hearing Scale (SSQ) short version (SSQ12) questionnaire, respectively. Results: A percentage of 41.38% of the case group and 44.4% of the control group experienced cisplatin-induced ototoxicity (CIO) according to NCI-CTCAE V.6 criteria. No significant difference was found between cases and controls regarding CIO measured by audiogram or data obtained from patients through the SSQ12 questionnaire. Conclusion: Use of atorvastatin (10 mg daily) was not significantly associated with a reduction in CIO, as assessed by change in hearing thresholds, CTCAE criteria, or SSQ12 questionnaire. Trial Registration: https://clinicaltrials.gov/study/NCT06553157 . Identifier: NCT06553157. Plain Language Summary: Background : Ototoxicity is a common adverse effect of cisplatin chemotherapy. Multiple studies investigated protective agents against CIO, and atorvastatin seems to have a potential benefit based on retrospective data. What we studied : We examined whether co-treatment with atorvastatin during cisplatin chemotherapy can protect against CIO. How the study was conducted : Patients were randomly assigned to case group (received atorvastatin 10 mg daily during cisplatin chemotherapy), and control group (no intervention). Patients received audiometric evaluations before and after treatment to assess the change in hearing status and whether there is a significant difference between the two groups. CTCAE V.6 criteria were used to grade hearing loss, and SSQ12 questionnaire was used at the end of treatment to assess hearing in everyday situations. What we found : Cisplatin showed significant ototoxicity. Treatment with atorvastatin at a dose of 10 mg daily was not associated with a statistically significant protective effect against CIO in the present study. Infographic about cisplatin-induced ototoxicity and an atorvastatin prevention study. Top section text: Cisplatin-induced Ototoxicity. 40 to 70 percent of treated patients are affected. Usually bilateral, high-frequency sensorineural hearing loss, irreversible. Assessed with audiometry (NCI-CTCAE V.6 criteria) and SSQ12 questionnaire. Lower section has three blocks connected in sequence. Rationale: Atorvastatin is a promising agent as it reduces oxidative stress (a main mechanism of CIO) and it improves vasodilation. Study design: 56 participants (29 cases and 27 controls) in an RCT to test the efficacy of Atorvastatin 10 mg daily to prevent CIO. Baseline and final audiograms (within 3 months from end of treatment) were used, as well as SSQ12 questionnaire. Results: 41.38 percent case group. 44.44 percent control group. No significant difference between the groups. p equals 0.70. Bottom statement: Atorvastatin 10 mg daily does not show an efficacy against CIO.An infographic summarizing cisplatin-induced ototoxicity and an atorvastatin 10 mg RCT result. Keywords: cisplatin-induced ototoxicity, CIO, atorvastatin, hearing loss, audiogram, SSQ12 questionnaire
Language: English
Subfield: Toxicology
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W7225461514
FWCI:
Cites:
Cited by:
Related to: 10